IP Group

New venture growth mandate boosts fee prospects

2 November 2026

IP Group has been appointed by Aberdeen Investments to manage a UK venture growth portfolio, via the CG Scottish Widows Growth LTAF (long term asset fund). This is one of the first initiatives to actively allocate UK pension scheme members' capital to UK venture growth - connecting patient institutional capital with British businesses of high potential. Building fee income is a strategic priority for IP Group and this mandate should be a key contributor to fee income growth.

In addition to supporting the pension fund's objectives, the mandate is designed to address a constraint on the UK innovation economy: **the availability of meaningful follow-on funding** for companies ready to commercialise and expand.

IP Group has announced that the first investments will be deployed across several strategically important areas of UK innovation, including quantum computing, advanced battery technology and AI-enabled healthcare.

It has said that these initial investments are expected to include *Oxford Quantum Circuits*, which is building commercially available quantum computing systems; *Quantum Motion*, which is building scalable silicon-based quantum computers designed for mass adoption; *Nyobolt*, whose ultra-fast-charging battery technology is advancing high-performance energy storage; and *Genomics Limited* which is applying AI, machine learning and large-scale genetic datasets to transform preventative healthcare and drug discovery.

CEO Greg Smith said: ***"We believe this is only the beginning of a much larger opportunity to unlock growth, support economic prosperity and deliver attractive long-term returns for savers."***

We have not made any adjustments to forecasts or valuation at this stage, but we point readers to our detailed commentary on IP Group's third-party fund management business and its growth prospects in our Sep 26 note: **Strong H1, exits up sharply, solid portfolio FV rise**.

We also direct readers to our recent interview with CEO Greg Smith and CFOO David Baynes which included a discussion on IP Group's third-party fund management business (including comments on this Aberdeen mandate). The full interview covering a much broader discussion about the group and its prospects can be viewed here.

Summary financials & forecasts

Year end 31 Dec, £m	FY23A	FY24A	H125A	FY25A	H126A	FY26E	FY27E
Net Asset Value (NAV)	1,190	953	883	975	1,006	1,000	1,067
NAV per share (p)	115	98	96	110	114	117	131
SP discount to NAV[1]	(49%)	(45%)	(46%)	(47%)	(43%)		
Cash invested	(74)	(63)	(36)	(71)	(30)	(70)	(70)
Cash proceeds	39	183	30	68	69	100	100
Net portfolio profit/(loss)	(161)	(195)	(44)	64	38	62	115
Third-party AUM	469	678	663	557	553	560	626
Fee & other income[2]	5.9	5.5	3.6	7.4	3.0	6.2	7.6
Group profit/(loss) before tax	(176)	(207)	(43)	65	40	43	97
EPS, basic (p)	(16.5)	(20.0)	(4.6)	7.2	3.5	3.9	11.6
Share buybacks	0	30	26	46	0	20	33
Buybacks (% of mkt cap)[3]	0.0%	5.6%	5.4%	8.8%	0.0%	3.9%	6.2%

Source: Company Historic Data, ED forecasts. PBT on disaggregated presentation basis. [1]Based on market cap at end of period. [2]Other income includes licensing & patent income. [3]Based on share/price/market cap at beginning of period.

Company Data

EPIC	IPO.L
Price (last close)	73p
52 weeks Hi/Lo	75p/49p
Market cap	£645m
ED Fair Value/share	111p
Avg. daily volume	1,629k

Share Price, p



Source: Investing.com

Description

IP Group (IPG) was founded in 2001 and is listed on the main market of the LSE. It invests in companies underpinned by IP and scientific innovation, across HealthTech, DeepTech, CleanTech. Investments are sourced via partnerships with universities (incl. Oxford, Cambridge, Imperial & UCL), research institutions and other networks.

The on-balance-sheet portfolio value is >£0.9bn, with >£0.5bn managed for 3rd parties. The portfolio has produced 5 unicorns and realised >£1.1bn.

Next event

FY26 results March 2027

Paul Bryant (Analyst)
0207 065 2690
paul.bryant@equitydevelopment.co.uk

Hannah Crowe
0207 065 2691
hannah@equitydevelopment.co.uk

Please refer to the important disclosures shown on the back page and note that this information is **Non-independent** and categorised as **Marketing Material**

Contacts

Andy Edmond
Direct: 020 7065 2691
Tel: 020 7065 2690
andy@equitydevelopment.co.uk

Hannah Crowe
Direct: 0207 065 2692
Tel: 0207 065 2690
hannah@equitydevelopment.co.uk

Equity Development Limited is regulated by the Financial Conduct Authority

Disclaimer

Equity Development Limited ('ED') is retained to act as financial adviser for its corporate clients, some or all of whom may now or in the future have an interest in the contents of this document. ED produces and distributes research for these corporate clients to persons who are not clients of ED. In the preparation of this report ED has taken professional efforts to ensure that the facts stated herein are clear, fair and not misleading, but makes no guarantee as to the accuracy or completeness of the information or opinions contained herein.

Any reader of this research should not act or rely on this document or any of its contents. This report is being provided by ED to provide background information about the subject of the research to relevant persons, as defined by the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever.

Research produced and distributed by ED on its client companies is normally commissioned and paid for by those companies themselves ('issuer financed research') and as such is not deemed to be independent as defined by the FCA but is 'objective' in that the authors are stating their own opinions. This document is prepared for clients under UK law. In the UK, companies quoted on AIM are subject to lighter due diligence than shares quoted on the main market and are therefore more likely to carry a higher degree of risk than main market companies.

ED may in the future provide, or may have in the past provided, investment banking services to the subject of this report. ED, its directors or persons connected may at some time in the future have, or have had in the past, a material investment in the Company. ED, its affiliates, officers, directors and employees, will not be liable for any loss or damage arising from any use of this document to the maximum extent that the law permits.

More information is available on our website www.equitydevelopment.co.uk